Fernandez-Blanco JI, et al. - Here, researchers evaluated the ability of adalimumab to achieve histological remission in ulcerative colitis (UC) patients. In anti-TNF naïve patients with moderately to severely active UC, adalimumab was able to achieve histological remission.

Methods

• Single-center, retrospective, open-label study of patients treated with adalimumab was performed.
• For this study, eligible patients were anti-TNF naïve adults with moderately to severely active UC.
• They performed the Mayo score including endoscopy at baseline and weeks 8 and 52.
• Using the Geboes Index, histological activity was scored.
• Histological remission was the primary endpoint, which was defined as a Geboes grade ≤ 3.0, at week 52.

Results

• A total of 34 patients were included.
• Six of 34 patients (17.6%) achieved histological remission at week 8.
• Nine patients (26.5%, intention to treat; 31%, per protocol) had histological remission at week 52.
• In the most severe subgrades of Geboes Index, patients had a significant and progressive reduction from baseline at weeks 8 and 52.
• Fifty percent and 61.8% of patients achieved mucosal healing (Mayo endoscopic subscore 0-1) at weeks 8 and 52.
• Furthermore, all patients who achieved histological remission had mucosal healing.
• In this study, 85.3 and 20.6% of patients achieved clinical response (decrease in Mayo score ≤ 3 points) or remission (Mayo score ≤ 2), respectively, at week 8.
• The corresponding values were 67.6 and 52.9%, respectively, at week 52.
• Agreement between histological remission and mucosal healing was fair (kappa 0.293) at week 52.
• Findings revealed that agreement between histological remission and Mayo endoscopic subscore 0 was good (kappa 0.71).